---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-052053"
form_type: "8-K"
ticker: "CERS"
cik: "0001020214"
company_name: "CERUS CORP"
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:44:16.702322+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cerus Q1 product revenue up 24% to $38.4M; net loss narrows to $9.7M; ReCePI trial met endpoint

## Summary
- Q1 product revenue $38.4M (+24% YoY); total revenue $43.4M (+13%).
- Net loss $9.7M ($0.05 EPS) vs $15.6M ($0.09) in Q1 2023; adjusted EBITDA -$2.7M.
- ReCePI Phase 3 trial for INTERCEPT Red Blood Cells met primary endpoint in cardiovascular surgery.
- FDA approved 12-month shelf life for INTERCEPT Platelet Processing Sets.
- FY2024 product revenue guidance reaffirmed at $172-175M; IFC guidance $8-10M.

## SEC filing metadata
- accession: 0000950170-24-052053
- form_type: 8-K
- ticker: CERS
- cik: 0001020214
- company_name: CERUS CORP
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/0000950170-24-052053-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/cers-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-052053
- JSON: https://secwatch.observer/filing/0000950170-24-052053.json
- Plain text: https://secwatch.observer/filing/0000950170-24-052053.txt

## Key facts
- Earnings Releases
  CERUS CORP updated its first quarter ended March 31, 2024 guidance (reaffirmed).
  - Period: first quarter ended March 31, 2024
  - Guidance: reaffirmed
  - Result: reported results
  source text: On May 2, 2024, Cerus Corporation (the “Company”) announced its financial results for its first quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1020214/000095017024052053/0000950170-24-052053-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.